Alnylam Pharmaceuticals taps Tenaya Therapeutics to uncover new cardiovascular RNAi drug targets
Alnylam Pharmaceuticals partners with Tenaya Therapeutics to discover RNAi targets for cardiovascular disease. Read the analysis behind this biotech collaboration.